Cancer clinical trials in the region Auvergne-Rhône-Alpes

518 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes
Phase 3 Liver and bile duct cancer #NCT06467357 #2023-508057-19-00
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy Antibody Drug Conjugates (ADC)
8 recruiting sites
AstraZeneca
Phase 3 Endometrial cancer #NCT05255653 #2023-503267-42-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Other
Required FIGO stages
Stage I Stage II Stage III
Required disease stage
Localized Locally Advanced
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Surgery
Excluded genetic anomalies
POLE
Excluded previous treatments at localized stage
Immunotherapy Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
10 recruiting sites
Centre médical universitaire de Leiden
Phase 3 Sarcoma and GIST #NCT06127407 #2023-508507-20-00
Required histologic types
Bone sarcoma
Required histologic sub types
Chondrosarcoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy Targeted therapy
9 recruiting sites
Phase 3 Prostate cancer #NCT05974774 #2023-506817-23-01
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
9 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3 Stomach and esophageal cancer #NCT06901531
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06960577 #2024-519246-75-01
Required histologic types
Invasive bladder cancer
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy
17 recruiting sites
AstraZeneca
Phase 3 Colon cancer Rectal cancer #NCT07549412 #2025-524648-37-00
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
EMD Serono Research & Development Institute, Inc.
Phase 3 Stomach and esophageal cancer #NCT07431281 #2024-519787-40-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Negative (< 1)
Excluded genetic anomalies
HER2
3 recruiting sites
AstraZeneca
Phase 3 Stomach and esophageal cancer #NCT07431281 #2024-519787-40-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
3 recruiting sites
AstraZeneca
Phase 3 Multiple myeloma #NCT07665450
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
2 recruiting sites
Janssen